Objectives: To present the data obtained from surgical specimens and biopsies of residual prostate and prostatic capsule, which in addition to the information provided by imaging tests give us the baseline situation of the prostatic surgical bed and residual prostate after transcervical hemostatic adenomectomy with capsule plasty. All this is the first step for the long-term study of its evolution and possible implications in the genesis of new obstructive or neoplastic pathology.

Methods: 70 consecutive cases of transcervical hemostatic adenomectomy with the variation of capsule plasty, recently developed, after a previous experience of 1033 retropubic surgeries. We analyze the histologic findings in surgical specimens, biopsies of residual gland and prostate capsule, and confirmed the immediate changes surgery causes, measuring the volumes of residual prostate by ultrasound. As the base for comparisons we analyzed residual prostates from prostatectomies or radical cystoprostatectomy specimens in "young" patients.

Results/conclusions: We obtained objective data about predominant and associated histological lesions found in adenomectomy specimens. In the same way, the same data were obtained from biopsies of peripheral residual prostate together with the volume of such zone, which should establish, if our hypothesis is right, the mid-long-term prognostic criteria for the approach to the so-called post operative reexpansion of the prostatic hollow and the possible establishment of new obstructive pathology.

Download full-text PDF

Source
http://dx.doi.org/10.4321/s0004-06142007000900003DOI Listing

Publication Analysis

Top Keywords

residual prostate
20
prostate prostatic
8
prostatic hollow
8
surgical specimens
8
specimens biopsies
8
biopsies residual
8
transcervical hemostatic
8
hemostatic adenomectomy
8
capsule plasty
8
residual
7

Similar Publications

Propose: This study aimed to evaluate the efficacy and safety of neoadjuvant treatment of darolutamide, a next-generation androgen receptor inhibitor, plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer (LAPC).

Methods: This single-arm, multicenter, open-label phase II trial (ClinicalTrials.gov: NCT05249712, 2022-01-01), recruited 30 localized high-risk/very high-risk prostate cancer (HRPCa/VHRPCa) patients from three centers in China between 2021 and 2023.

View Article and Find Full Text PDF

Background: Focal therapy is considered one of the treatment options for localized prostate cancer (PCa), particularly for low or very-low-risk patients. In this study, we compared the mid-term oncological outcomes in localized PCa patients treated with high-intensity focused ultrasound (HIFU).

Methods: We retrospectively analyzed 237 patients who underwent HIFU for localized PCa.

View Article and Find Full Text PDF

To compare the efficacy and safety of low-power holmium laser enucleation of the prostate (LP-HoLEP) with plasma kinetic resection of prostate (PKRP). Sixty-three patients treated with transurethral LP-HoLEP (observation group) and 68 patients treated with transurethral PKRP (control group) at Beijing Hospital of Traditional Chinese Medicine from November 2019 to November 2022 were retrospectively compared with regard to operation duration, intra-operative blood loss, prostate resection ratio, postoperative bladder irrigation time, postoperative indwelling urinary catheter time, postoperative urinary incontinence incidence, International Prostate Symptom Scale (IPSS), maximum urine flow rate (Qmax), and residual urine volume (RUV). In both groups, postoperative IPSS, Qmax, and RUV were significantly improved compared to preoperative values (P < 0.

View Article and Find Full Text PDF

Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical trials of HIFU on PCa.

View Article and Find Full Text PDF

MRI-guided focal laser ablation (MRI-FLA) is an emerging minimally invasive technique for treating localized prostate tumors, aiming to provide effective cancer control while minimizing side effects. This meta-analysis systematically evaluates the clinical outcomes, technical efficacy, and complication rates associated with MRI-FLA to better understand its therapeutic potential and safety profile in prostate cancer management. In July 2024, PubMed (MEDLINE) was searched for eligible trials using the PRISMA guidelines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!